 |
인쇄하기
취소
|
DHP Korea and Dongwha enter agreement over Zabofloxacin
DHP Korea and Dongwha Pharmaceutical has recently announced an agreement granting DHP exclusive rights to develop and commercialize Zabofloxacin (DW224a) in the field of ophthalmology.
DHP plans to develop Zabofloxacin for the treatment of ophthalmic diseases.
Zabofloxacin is a fluoroquinolone antibiotic with enhanced in-vitro activity against Streptococcus pneumoniae, including strains r...
DHP plans to develop Zabofloxacin for the treatment of ophthalmic diseases.
Zabofloxacin is a fluoroquinolone antibiotic with enhanced in-vitro activity against Streptococcus pneumoniae, including strains r...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.